Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far.

Joe Lavorgna Talks US Economy, Bond Market
14:34

Jeff Currie Talks AI Boom and Commodities
08:52

Liberty Media CEO Derek Chang
06:43